Stagliano Nancy 4
4 · Pandion Therapeutics, Inc. · Filed Jul 21, 2020
Insider Transaction Report
Form 4
Stagliano Nancy
Director
Transactions
- Conversion
Series A Preferred Stock
2020-07-21−28,620→ 0 total(indirect: By Trust)→ Common Stock (5,612 underlying) - Purchase
Common Stock
2020-07-21$18.00/sh+1,000$18,000→ 1,000 total - Conversion
Common Stock
2020-07-21+15,004→ 73,067 total(indirect: By Trust) - Award
Stock Option (right to buy)
2020-07-17+13,997→ 13,997 totalExercise: $18.00Exp: 2030-07-16→ Common Stock (13,997 underlying) - Conversion
Series B Preferred Stock
2020-07-21−47,898→ 0 total(indirect: By Trust)→ Common Stock (9,392 underlying) - Award
Stock Option (right to buy)
2020-07-17+3,674→ 3,674 totalExercise: $18.00Exp: 2030-07-16→ Common Stock (3,674 underlying)
Footnotes (4)
- [F1]The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share.
- [F3]This option award was granted on July 17, 2020. The shares underlying the award vest in equal quarterly installments following June 28, 2018 through June 28, 2022, subject to the reporting person's continued service on each applicable vesting date.
- [F4]This option award was granted on July 17, 2020. The shares underlying the award vest in equal monthly installments following July 17, 2020 through July 17, 2023, subject to the reporting person's continued service on each applicable vesting date.